Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Awarded OLINVYK Agreement with Premier, Inc.

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
November 30, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
November 14, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable...
November 09, 2023 07:00 ET | Source: Trevena, Inc.

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
October 16, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia,...
October 02, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into...
September 06, 2023 07:01 ET | Source: Trevena, Inc.

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION...
September 06, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant...
August 14, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Reports Second Quarter 2023 Results and Provides Business Update

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for...
July 20, 2023 07:00 ET | Source: Trevena, Inc.

Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...